Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19

AUTOR(ES)

Barbosa, Alexandre Naime; Silvinato, Antonio; Bacha, Hélio; Floriano, Idevaldo; Tanni, Suzana; Bernardo, Wanderley

FONTE

Revista da Associação Médica Brasileira

DATA DE PUBLICAÇÃO

2022

RESUMO

Documentos Relacionados

• Evidence for early disease-modifying drugs in rheumatoid arthritis
• Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes
• Glucosamine: A potential disease-modifying agent in osteoarthritis?
• Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
• Step‐up combination versus switching of non‐biological disease‐modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study